PREX2 and lung carcinoma: Previous research have demonstrated that lung cancer patients with COPD had certain characteristics that suggested they may benefit from immunotherapy, such as high TMB, high tumor neo-antigen burden (TNB), high mutation frequencies of immune-related genes like LRP1B and PREX2, and low mutation frequency of EGFR [21, 22].